Skip to main content
OpenTrials

Clinical trial condition

Relapsed/Refractory Multiple Myeloma

Explore clinical trials studying Relapsed/Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

51 public trials 21 recruiting studies
Refine in advanced search Browse all conditions

Relapsed/Refractory Multiple Myeloma trial results

Recruiting

A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

NCT06049290

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • The First Affiliated Hospital of Wannan Medical College Wuhu, Anhui, China
  • Peking University People's Hospital Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View all 21 locations
View Trial Details
Recruiting

A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma

NCT07493135

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beijing GoBroad Boren Hospital Beijing, China
  • The second affiliated hospital of Chongqing medical university Chongqing, China
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China
  • Zhengzhou Yihe Hospital Zhengzhou, China
View Trial Details
Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • LKH Leoben Leoben, Austria
  • Krankenhaus der barmherzigen Schwestern Vienna, Austria
  • UZ Antwerpen Edegem, Belgium
  • Ziekenhuis Oost-Limburg Genk, Belgium
View all 90 locations
View Trial Details
Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT04973605

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • City of Hope National Medical Center Duarte, California, United States
  • City of Hope Irvine Lennar Irvine, California, United States
  • University of Miami Miami, Florida, United States
View all 82 locations
View Trial Details
Recruiting

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

NCT05850234

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Phoenix, Arizona, United States
  • Research Site La Jolla, California, United States
  • Research Site Los Angeles, California, United States
View all 36 locations
View Trial Details
Recruiting

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT07284758

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • HonorHealth Scottsdale, Arizona, United States
  • Berenson Cancer Center West Hollywood, California, United States
  • Winship Cancer Institute, Emory University Atlanta, Georgia, United States
  • Indiana University Health Indianapolis, Indiana, United States
View all 21 locations
View Trial Details
Recruiting

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT06669247

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Royal Prince Alfred Hospital Sydney, New South Wales, Australia
  • Illawarra Cancer Care Centre Wollongong, New South Wales, Australia
  • Pindara Private Hospital Benowa, Queensland, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
View Trial Details
Recruiting

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

NCT07454187

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital Of Soochow University Suzhou, Jiangsu, China
  • The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital) Xi’an, Shanxi, China
  • The Second Affiliated Hospital Zhejiang University School Of Medicine Hangzhou, Zhejiang, China
View Trial Details
Recruiting

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

NCT06508983

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beijing Chaoyang Hospital of Capital Medical University Beijing, Beijing Municipality, China
  • Guangzhou First People's Hospital Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • First Affiliated Hospital of Henan University of Science and Technology Luoyang, Henan, China
View Trial Details

Related conditions